Integral Health Asset Management LLC Invests $4.53 Million in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)

Integral Health Asset Management LLC purchased a new position in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 100,000 shares of the biopharmaceutical company’s stock, valued at approximately $4,525,000. Integral Health Asset Management LLC owned 0.94% of Corbus Pharmaceuticals at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the stock. Ikarian Capital LLC boosted its holdings in shares of Corbus Pharmaceuticals by 185.5% in the first quarter. Ikarian Capital LLC now owns 559,271 shares of the biopharmaceutical company’s stock worth $21,946,000 after acquiring an additional 363,372 shares during the period. Vanguard Group Inc. boosted its stake in Corbus Pharmaceuticals by 143.7% during the first quarter. Vanguard Group Inc. now owns 437,264 shares of the biopharmaceutical company’s stock valued at $17,158,000 after buying an additional 257,808 shares during the period. Janus Henderson Group PLC bought a new stake in Corbus Pharmaceuticals during the first quarter valued at $13,363,000. Price T Rowe Associates Inc. MD bought a new stake in Corbus Pharmaceuticals during the first quarter valued at $7,554,000. Finally, Altitude Crest Partners Inc. bought a new stake in Corbus Pharmaceuticals during the first quarter valued at $4,069,000. 64.64% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms recently issued reports on CRBP. HC Wainwright reissued a “buy” rating and set a $80.00 price objective on shares of Corbus Pharmaceuticals in a research note on Tuesday, August 6th. Royal Bank of Canada reissued an “outperform” rating and set a $82.00 price objective on shares of Corbus Pharmaceuticals in a research note on Friday. Lifesci Capital raised Corbus Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, August 21st. B. Riley dropped their price target on Corbus Pharmaceuticals from $85.00 to $40.00 and set a “buy” rating for the company in a research note on Friday. Finally, Mizuho reaffirmed an “outperform” rating and set a $74.00 price target on shares of Corbus Pharmaceuticals in a research note on Friday. One research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Corbus Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $65.86.

Corbus Pharmaceuticals Trading Down 62.3 %

CRBP opened at $19.51 on Monday. The company has a market cap of $208.50 million, a P/E ratio of -2.80 and a beta of 2.56. The business’s 50-day moving average price is $55.03 and its 200-day moving average price is $47.11. Corbus Pharmaceuticals Holdings, Inc. has a 12 month low of $3.03 and a 12 month high of $61.90.

Corbus Pharmaceuticals (NASDAQ:CRBP) last released its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.90) EPS for the quarter, topping the consensus estimate of ($1.19) by $0.29. Equities research analysts forecast that Corbus Pharmaceuticals Holdings, Inc. will post -3.77 earnings per share for the current fiscal year.

Corbus Pharmaceuticals Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.